Kratos Defense & Security Solutions announced it will release its third quarter 2026 financial results after market close on November 5, 2026. The company will hold a conference call at 2:00 p.m. Pacific Time to discuss its operations and financial performance. Investors and interested parties can register online to participate or listen to a replay later on Kratos' website. This call provides insight into Kratos' ongoing business in defense technology and its strategic developments in areas like unmanned systems and hypersonics.
Kratos Defense & Security Solutions announced its third quarter 2026 earnings call scheduled for November 5th. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Oct 26, 2026 18:12 WIB: out of 135 stocks, 69 rose and 33 fell. Among notable movers, EHang Holdings Ltd (EH) rose 1.62% to USD 3.45 with a typical hold time of 48 days, contrasting with DHT Holdings Inc. (DHT) which gained 1.42% to USD 24.95 but has a much shorter typical hold time of 6 days.
Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices ...
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
FOREWARN, a safety solutions provider for real estate professionals, introduced Community Alerts, a new feature that allows agents to flag phone numbers after concerning interactions. This alert is instantly shared across its network of over 443,000 ...
Franklin Electric Co., Inc. announced a quarterly cash dividend of $0.28 per share, payable on November 19, 2026, to shareholders of record as of November 5, 2026. This dividend reflects the company's ongoing commitment to returning value to its shar...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
